breast cancer

An arrow incrementally going up stairs before pointing straight up Blue background

Biotech

Roche links SERD to 30% breast cancer risk reduction in phase 3

Roche reported a 30% reduction in the risk of invasive disease recurrence or death in patients on its oral selective estrogen receptor degrader.

Nick Paul Taylor Dec 10, 2025 8:15am

Graphic image of an arrow nailing the bullseye of a target

Roche's oral SERD hits goal in adjuvant breast cancer phase 3

Nov 18, 2025 9:16am

Blue race track

Fierce Pharma

Merck grows more ambitious about 'workhorse' TROP2 ADC

Oct 20, 2025 4:00pm

Roche ESMO

ESMO: Roche wants oral SERD to benefit 'all comers'

Oct 18, 2025 1:00am

BMS ESMO Bristol Myers Squibb

ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals

Oct 17, 2025 10:30am

breast cancer mammogram

Spanish oncology group infuses AI into breast cancer trials

Oct 7, 2025 6:05am